Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease

Neurochemical Research

Volumn 36, Issue 3, 2011, Pages 367-374

  Yong, Yue ^a   Ding, Hanqing ^a   Fan, Zhiqin ^a   Luo, Jia ^a,b   Ke, Zun Ji ^a  

^a Graduate School   (China)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

6 ohda; Dopaminergic neurons; Glycogen synthase kinase 3; Lithium; Parkinson's disease

Indexed keywords

CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; SERINE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; MALE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOLYTICS;

ANIMALIA; RATTUS;

EID: 79954421190     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0368-z     Document Type: Article

References (30)

1. Schapira AH, Olanow CW (2008) Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 64:S47-S55.
2. Marmol F (2008) Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 32:1761-1771.
3. Wada A (2009) Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 110:14-28.
4. Chuang DM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16:83-90.
5. Dill J, Wang H, Zhou F et al (2008) Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 28:8914-8928.
6. Fornai F, Longone P, Cafaro L et al (2008) Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105:2052-2057. (Pubitemid 351439463)
7. Martinez A, Perez DI (2008) GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15: 181-191.
8. Sarkar S, Krishna G, Imarisio S et al (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17:170-178.
9. Wei H, Leeds PR, Qian Y et al (2000) beta-amyloid peptideinduced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol 392:117-123. (Pubitemid 30184897)
10. Wei H, Qin ZH, Senatorov VV et al (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106:603-612. (Pubitemid 32925248)
11. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:1313-1317. (Pubitemid 38802652)
12. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426. (Pubitemid 32781670)
13. Luo J (2009) GSK3beta in Ethanol Neurotoxicity. Mol Neurobiol 40:108-121.
14. Chen G, Bower KA, Ma C et al (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18:1162-1164. (Pubitemid 39561557)
15. Chen YY, Chen G, Fan Z et al (2008) GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells. Biochem Pharmacol 76:128-138.
16. Wang W, Yang Y, Ying C et al (2007) Inhibition of glycogen synthase kinase-3 beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52:1678-1684. (Pubitemid 46843143)
17. Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46:1130-1140. (Pubitemid 38529937)
18. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11:151-167.
19. DauerW PrzedborskiS (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909. (Pubitemid 37130207)
20. Franlin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego.
21. Nonaka S, Chuang DM (1998) Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9:2081-2084. (Pubitemid 28300570)
22. Wang X, Fan Z, Wang B et al (2007) Activation of doublestranded RNA-activated protein kinase by mild impairment of oxidative metabolism in neurons. J Neurochem 103:2380-2390. (Pubitemid 350173586)
23. Ke ZJ, DeGiorgio LA, Volpe BT et al (2003) Reversal of thiamine deficiency-induced neurodegeneration. J Neuropathol Exp Neurol 62:195-207. (Pubitemid 36176954)
24. Truong L, Allbutt H, Kassiou M et al (2006) Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 169:1-9. (Pubitemid 43277465)
25. Zuch CL, Nordstroem VK, Briedrick LA et al (2000) Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 427: 440-454.
26. Liu Y, Chen G, Ma C et al (2009) Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to ethanol toxicity. J Neurosci Res 87:2793-2802.
27. Rowe MK, Chuang DM (2004) Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 6:1-18.
28. Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441-443. (Pubitemid 37088166)
29. Petit-Paitel A, Brau F, Cazareth J et al (2009) Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One 4:e5491.
30. Olanow CW, Kordower JH (2009) Modeling Parkinson's disease. Ann Neurol 66:432-436.